Results from a recent paper indicates that nearly a quarter of women receive a diagnosis of osteoporosis in any given year. The reasons for these trends need to be determined. While the number of patients affected by postmenopausal osteoporosis has been clearly defined, patients with idiopathic postmenopausal osteopenia are not adequately diagnosed and treated. These patients are at higher risk of osteoporotic fracture.
Osteoporosis prevention is important after menopause. An early evaluation and effective intervention can prevent the occurrence of osteopenia and osteoporosis while treating other osteopenic characteristics, such as vertebral fractures, postmenopausal arthritis and osteopenia, and is especially important for younger patients who are at risk.
Postmenopausal women with osteoporosis have higher rates of cardiovascular mortality, noncancer death and major CV events, and the cause of CVD death and noncancer mortality is not attributable to OV.
The most common bone defects encountered by surgeons are osteoporotic fractures. The osteoporotic fractures most common to surgeons are the proximal radius fractures and distal tibia fractures. If the patient has a history or findings of osteoporosis, and is elderly, it is recommended that they have a bone density scan on the basis of a fracture.
About one third of women have osteoporosis. Common treatments for postmenopausal women with osteoporosis and osteopenia include estrogen replacement therapy and calcium and vitamin D supplements. Although these medications may provide some protection, they do not address risk in early postmenopause.\n
The main symptoms of osteoporosis include a low bone mineral density (BMD), long bone fracture and spinal stenosis (narrowing of the discs), all of which can be treated. Other symptoms may include a painful joint, numbness and tingling, fatigue and backache. In children, it may cause bowing of the growth plate and bone malformation.\n\nIf you are diagnosed with any of the symptoms above, seek medical attention immediately and get yourself to the doctor immediately (you may not remember exactly what the exact symptoms were).
There is no reliable epidemiologic evidence on the prevalence of osteoporosis and its complication in an elderly population. As there are no guidelines (e.g., the guidelines of the Dutch College of General Practitioners and the German Society of Internal Medicine) for deciding when to start a clinical trial on osteoporosis, the treatment decisions should be based on the individual history of the patient, medical history of the patient, available treatment options, and the patient's desires in regard to the treatments.
There are a number of treatment options available to individuals diagnosed with osteoporosis, but the most widely cited evidence-based treatment recommendations are the bisphosphonate medications. [The American College of Physicians recognizes] the evidence for these medications is strongest for treatment of moderate to severe osteoporosis, where there is a demonstrable reduction in fracture risk and fracture number when provided for at least three years. [When medications are used at a low enough dose to reduce fractures but not at a level that reduces normal skeletal turnover, then it is considered a “pharmacologic fracture” in the medical community.
Recent findings highlights that no single mechanism can explain the antiresorptive effects of alendronate, which were seen with all treatments. This suggests that alendronate exerts its antiresorptive effects by a multitude of mechanisms involving, not only changes in bone turnover, but also increased osteoprotegerin levels, which inhibit the effects of osteoclasts, bone resorption, thus leading to a reduction in bone mass. The authors conclude that treatment modalities, besides the timing and regimen, may play a significant role in determining which patient gets antiresorptive treatment, and thus how well the alendronate achieves its antiresorptive effects.
Most research has provided evidence to support the use of treatment to prevent osteoporosis and fracture. These treatments include alendronate, risedronate, estrogens, bisphosphonates, raloxifene, hormone replacement therapy, estrogens alone or with a selective estrogen receptor modulator, and phytehormone treatment. As a result of these findings, the U.S.
Osteoporosis in postmenopausal women is a significant health problem. Patients should be aware of the risks of developing osteoporosis, and the value of monitoring their bone mineral density should be emphasized.
Evidence in favour of the use of FRAX® calculator, as opposed to clinical judgment, in guiding osteoporosis treatment, was presented, based on the fact that both groups had similar rate of treatment initiation, occurrence of major adverse events, and no major adverse events were recorded in the FRAX group. We agree with this finding and suggest that such evidence is potentially worthy of a larger review. Further research is needed to investigate what effect the use of FRAX calculator could have on the decision to initiate treatment, in the light of the large number of people who do not receive treatment for osteoporosis each year in the UK.